ISA2015 | Clinical Breakthroughs
Dr. Paul Barton Duell (endocrinologist, Portland, USA) presented a striking reduction of MACE with treatment with the antisense oligonucleotide against apoB mRNA mipomersen in a very high risk population.
News • 4-8-2014
The Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society has reviewed the available data and established recommendations for improved diagnosis and management of HoFH.
News • 25-5-2015
ISA 2015 Using a humanised mouse model, investigators reveal mechanism via which CETP-inhibitor anacetrapib reduces non-HDL-c.
News • 24-5-2015
ISA 2015 Herman Kempen (Zurich, Switzerland) presented a new drug that may reduce the atherosclerotic plaque. MDCO-216, a complex of dimeric recombinant apolipoprotein A-1 Milano and a phospholipid (POPC), developed to mimic pre-beta HDL, induced ABCA1 mediated cholesterol efflux, and rapid HDL remodeling was seen. MDCO-216 was well tolerated.
News • 23-3-2015
European Atherosclerosis Society has launched global EAS FH Studies Collaboration (FHSC), which aims to address gaps in FH care and education worldwide, to promote early diagnosis and better treatment.
News • 18-3-2015
Phase 2b results show that ETC-1002 (bempedoic acid) safely and effectively lowers LDL-c levels when added to stable statin therapy, as compared with statin therapy alone.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.